Wednesday, December 31, 2014

Top Life Sciences Stocks To Own Right Now

With shares of General Electric (NYSE:GE) trading around $27, is GE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

General Electric is a diversified industrial, technology, and financial services company that operates worldwide. The products and services of the company range from aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products. General Electric�� segments are Energy Infrastructure, Aviation, Healthcare, Transportation, Home & Business Solutions, and GE Capital. General Electric is a leading provider of a wide range of products and many are essential in daily lives of consumers and companies around the world.

General Electric on Monday continued its push to expand its healthcare operation, agreeing to acquire certain life science assets of Thermo Fisher Scientific for $1.06 billion in cash.�The deal includes Waltham, Mass.-based Thermo Fisher’s cell culture, gene modulation, and magnetic bead businesses. The units, part of Thermo Fisher’s analytical technologies segment, generated combined revenue of about $250 million in 2013.�Fairfield, Conn.-based GE has been seeking to refocus its sprawling collection of businesses since the economic downturn, and looking to divest its consumer finance operations and to grow in healthcare and energy. The company said the Thermo Fisher units would be folded into its $4 billion-sales GE Healthcare life sciences business, giving it a more complete portfolio of tools used for cell biology research, cell therapy and for the manufacture of new biological medicines and vaccines.

Top Life Sciences Stocks To Own Right Now: Westlake Chemical Corporation(WLK)

Westlake Chemical Corporation manufactures and markets basic chemicals, vinyls, polymers, and fabricated building products. It operates in two segments, Olefins and Vinyls. The Olefins segment provides ethylene, polyethylene, styrene monomer, and various ethylene co-products, such as chemical grade propylene, crude butadiene, pyrolysis gasoline, and hydrogen. The Vinyls segment offers polyvinyl chloride (PVC), vinyl chloride monomer, ethylene dichloride, chlorine, caustic soda, and ethylene. This segment also manufactures and sells products fabricated from PVC, including water, sewer, irrigation, and conduit pipes; window and door profiles; and fences. The company?s products are used in various applications, such as consumer and industrial markets comprising flexible and rigid packaging, automotive products, coatings, and residential and commercial construction, as well as in other durable and non-durable goods. Westlake Chemical Corporation provides its products for chem ical processors, plastics fabricators, construction contractors, municipalities, and supply warehouses in the United States, Canada, Singapore, and internationally. The company was founded in 1985 and is headquartered in Houston, Texas.

Advisors' Opinion:
  • [By Rich Duprey]

    Specialty chemicals producer�Westlake Chemical� (NYSE: WLK  ) �has acquired�the PVC pipe, fittings, profiles, and foundation business of CertainTeed now that�all the closing conditions, including a regulatory review, have been met.

Top Life Sciences Stocks To Own Right Now: Conversant Inc (CNVR)

Conversant Inc, incorporated on October 9, 1998, is a digital marketing services company. The Company offers an integrated personalization platform, personalized media programs and the affiliate marketing network. The Company operates in two segments: Affiliate Marketing and Media. The Company delivers a range of solutions, from hyper-personalized creative and media, to campaign-based media where each person is individually selected for target audience based upon its profiles, to the set of affiliate marketing solutions. The Company has sold the Owned and Operated Websites segment and technology is included in the Media segment. In February 2014, Conversant Inc completed the acquisition of SET Media, a digital video technology company.

Affiliate Market Segment

The Company�� Affiliate Marketing segment operates under the Commission Junction brand name. The Affiliate Marketing segment provides the technology; network and customer service that, in combination, enable advertisers to create its commissioned online sales force comprised of third-party Website publishers, also known as affiliates.

Media Segment

The Company�� Media segment is a display ad network, provides a digital marketing services and tailored programs that help marketers create awareness for their products and brands, attract visitors and generate leads and sales through the Internet and mobile applications. The Media segment also includes the Company's Mediaplex business, which offers technology products and services that enable marketers to implement and manage their online advertising across multiple channels including display, email, paid search, natural search, on-site, offline, and affiliate.

Advisors' Opinion:
  • [By Luke Jacobi]

    Conversant (NASDAQ: CNVR) shares shot up 30.3 percent to $34.80 after Alliance Data Systems (NYSE: ADS) announced its plans to buy Conversant for $35 per share.

  • [By Garrett Cook]

    Toward the end of trading Friday, the Dow traded down 0.60 percent to 16,947.43 while the NASDAQ declined 0.75 percent to 4,557.59. The S&P also fell, dropping 0.83 percent to 1,980.97.

    Leading and Lagging Sectors Cyclical consumer goods & services shares fell by just 0.50 percent in trading on Friday. Top gainers in the sector included ULTA Salon, Cosmetics & Fragrance NASDAQ: (ULTA), up 17.5 percent, and 1-800-Flowers.com (NASDAQ: FLWS), up 4.5 percent. In trading on Friday, utilities shares were relative laggards, down on the day by about 1.89 percent. Meanwhile, top decliners in the sector included Companhia Energética de Minas Gerais - CEMIG (NYSE: CIG), down 4.7 percent, and CPFL Energia SA (NYSE: CPL), off 4.3 percent. Top Headline Darden Restaurants (NYSE: DRI) reported better-than-expected fiscal first quarter earnings. The Orlando, Florida-based company reported a quarterly loss of $19.3 million, or $0.14 per share, versus a year-ago profit of $42.2 million, or $0.32 per share. Excluding non-recurring items, the company earned $0.32 per share. Its sales surged to $1.6 billion versus $1.53 billion. However, analysts were expecting earnings of $0.30 per share on revenue of $1.6 billion. Equities Trading UP Conversant (NASDAQ: CNVR) shares shot up 30.25 percent to $34.79 after Alliance Data Systems (NYSE: ADS) announced its plans to buy Conversant for $35 per share. Shares of ULTA Salon, Cosmetics & Fragrance (NASDAQ: ULTA) got a boost, shooting up 17.69 percent to $114.72 after the company reported upbeat second-quarter results and raised its outlook. The company also unveiled a five-year plan for impressive growth. Sportsman's Warehouse Holdings (NASDAQ: SPWH) shares were also up, gaining 15.89 percent to $7.00 after the company reported stronger-than-expected fiscal second-quarter results. Equities Trading DOWN Shares of Ruckus Wireless (NASDAQ: RKUS) were down 5.19 percent to $14.35. Buckingham
  • [By Garrett Cook]

    Conversant (NASDAQ: CNVR) shares shot up 30.34 percent to $34.81 after Alliance Data Systems (NYSE: ADS) announced its plans to buy Conversant for $35 per share.

Best Penny Stocks To Invest In Right Now: Forward Air Corp (FWRD)

Forward Air Corporation operates in two segments: Forward Air, Inc. (Forward Air) and Forward Air Solutions, Inc. (FASI). Through the Company's Forward Air segment, it is a provider of time-definite surface transportation and related logistics services to the North American deferred air freight market. It offers its customers local pick-up and delivery (Forward Air Complete) and scheduled surface transportation of cargo. It transports cargo that must be delivered at a specific time but is less time-sensitive than traditional air freight. As of December 31, 2011, it operated its Forward Air segment through a network of terminals located on or near airports in 85 cities in the United States and Canada, including a central sorting facility in Columbus, Ohio and 12 regional hubs serving key markets. It also offers its customers an array of logistics and other services including expedited full truckload (TLX); dedicated fleets; warehousing; customs brokerage; and shipment consolidation, deconsolidation and handling. During the year ended December 31, 2011, approximately 23.9% of the freight it handled was for overnight delivery, approximately 61.3% was for delivery within two to three days and the balance was for delivery in four or more days. Through its FASI segment, it provides pool distribution services throughout the Mid-Atlantic, Southeast, Midwest and Southwest continental United States. Pool distribution involves managing high-frequency, last mile handling and distribution of time-sensitive product to destinations in geographic regions. In March 2013, it acquired Total Quality, Inc. In February 2014, Forward Air Corporation acquired Central States Trucking Co. and Central States Logistics, Inc. from Central States Inc.

Forward Air

The Company receives freight from air freight forwarders, integrated air cargo carriers and passenger and cargo airlines at its terminals, which are located on or near airports in the United States and Canada. It also picks up freight from custo! mers at designated locations via our Forward Air Complete service. It transports these shipments by truck through its network to its terminals nearest the destinations of the shipments. It operates scheduled service to and from each of its terminals through its Columbus, Ohio central sorting facility or through one of its 12 regional hubs. It also operates scheduled shuttle service directly between terminals where the volume of freight warrants bypassing the Columbus, Ohio central sorting facility or a regional hub. When a shipment arrives at its terminal nearest its destination, the customer arranges for the shipment to be picked up and delivered to its final destination, or it, in the alternative, through its Forward Air Complete service, deliver the freight for the customer to its final destination. Its airport-to-airport network consists of terminals located in the 85 cities. As of December 31, 2011, independent agents and FASI operate 18 and two of its Forward Air locations.

The Company operates direct terminal-to-terminal services and regional overnight service between terminals where justified by freight volumes. It provides regional overnight service to the markets within its network. Direct shipments also reduce the likelihood of damage because of reduced handling and sorting of the freight. It operates regional hubs in Atlanta, Charlotte, Chicago, Dallas/Ft. Worth, Denver, Kansas City, Los Angeles, New Orleans, Newark, Newburgh, Orlando, and Sacramento. During 2011, the average weekly volume of freight moving through its network was approximately 34.0 million pounds per week. During 2011, its average shipment weighed approximately 717 pounds and shipment sizes ranged from small boxes weighing only a few pounds to large shipments of several thousand pounds.

The Company�� logistics and other services allow customers to access services from a single source: expedited full truckload (TLX); dedicated fleets; customs brokerage, such as assistance with the United States C! ustoms an! d Border Protection (U.S. Customs) procedures for both import and export shipments; warehousing, dock and office space; drayage and intermodal; hotshot or ad-hoc ultra expedited services, and shipment consolidation and handling, such as shipment build-up and break-down and reconsolidation of air or ocean pallets or containers.

Forward Air Solutions

Through the Company�� FASI segment, it provides pool distribution services through a network of terminals and service locations in 19 cities throughout the Mid-Atlantic, Southeast, Midwest and Southwest continental United States. Pool distribution involves managing high-frequency handling and distribution of time-sensitive product to destinations in specific geographic regions. Its customers for this product are regional and nationwide distributors and retailers, such as mall, strip mall and outlet-based retail chains. Its pool distribution network consists of terminals and service locations in the 19 cities. Its Forward Air wholesale customer base is comprised of freight forwarders, integrated air cargo carriers and passenger and cargo airlines. Its air freight forwarder customers vary in size from independent, single facility companies to international logistics companies, such as SEKO Worldwide, AIT Worldwide Logistics, Expeditors International of Washington, Associated Global, UPS Supply Chain Solutions and Pilot Air Freight. Its FASI pool distribution customers are consisted of national and regional retailers and distributors, such as The Limited, The Marmaxx Group, The GAP, and Aeropostale. The Company also participates in air cargo and retail trade shows and advertise its services through direct mail programs and through the Internet via www.forwardair.com and www.forwardairsolutions.com.

Advisors' Opinion:
  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Forward Air (Nasdaq: FWRD  ) , whose recent revenue and earnings are plotted below.

Top Life Sciences Stocks To Own Right Now: Kabe Exploration Inc (KABX)

Kabe Exploration Inc., incorporated on December 15, 2005, is an exploration stage company. The Company focuses to drill shallow wells 3300-6000 feet. on a turnkey basis.

On February 21, 2013, Kabe purchased 320 Mineral lease acres in Butler County Kansas representing a 81% Net Revenue Interest. As of December 31, 2012, the Company did not generate any revenues.

Advisors' Opinion:
  • [By CRWE]

    Today, KABX surged (+25.00%) up +0.0020 at $.0100 with�309,514 shares in play thus far (ref. google finance Delayed: 12:06PM EDT July 9, 2013).

    Kabe Exploration, Inc. previously reported it has secured a bridge loan with Phoenix Group Capital Markets, a UK holding company, through its wholly owned micro-cap investment fund. The bridge loan was secured with restricted stock for operating capital purposes. The company had previously entered into a $5,000,000 Reserve Equity Financing Agreement with Phoenix Group in a term sheet announced in May. ��his bridge loan affirms the level of investment confidence we are seeing from the professional investment community,��said Erik Ulsteen, the company�� CE

Top Life Sciences Stocks To Own Right Now: Opus International Consultants Ltd (OIC)

Opus International Consultants Limited is a supplier of multidisciplinary consultancy and project management services across a range of disciplines including, civil, mechanical and electrical engineering, and planning, environmental, architectural and property management. The Company operates in four segments: New Zealand, United Kingdom, Australia and Canada. Services supplied support asset development and asset management activities of the Company�� clients. Asset management services include property management and asset maintenance services predominantly using our engineering and environmental specialists. Asset development services include civil, mechanical and electrical engineering, planning, environmental and architectural work. Effective September 3, 2013, Opus International Consultants Ltda majority-owned unit of Opus Group Bhd acquired Stewart, Weir & Co Ltd. Advisors' Opinion:
  • [By John McCamant]

    Nektar Therapeutics (NKTR) is expected to get FDA approval this year for its lead drug naloxegol, a once-a-day pill for opioid-induced constipation (OIC). The drug is licensed to AstraZeneca. NKTR will receive up to $245 million in milestone payments, plus royalties.

Top Life Sciences Stocks To Own Right Now: VisionChina Media Inc.(VISN)

VisionChina Media Inc., through its subsidiaries, provides advertising services in the People?s Republic of China. The company operates out-of-home advertising network using real-time mobile digital television broadcasts to deliver content and advertising on mass transportation systems. Its mobile digital television advertising network delivers real-time content provided by the local television stations. The company?s network also displays real-time news and stock quotes, weather and traffic updates, sports highlights, and other programs, as well as disseminates public-interest messages and programs that promote the general welfare of society and other urgent messages during emergency situations, such as typhoons, earthquakes, and other events that concern public safety. Its advertising network consists of digital television displays primarily located on buses, and in subway trains and subway platforms that receive mobile digital television broadcasts of real-time conten t and advertising. The company also operates various closed-circuit advertising digital displays in subway platforms and subway trains in Beijing, Chongqing, Guangzhou, Nanjing, Shenzhen, and Tianjin, as well as in subway trains in Hong Kong. As of December 31, 2010, its network and supplemental subway advertising platform covered 23 cities in China and consisted of approximately 137,395 digital displays. The company sells its advertising time through direct sales force and third party advertising agencies. VisionChina Media Inc. was founded in 2005 and is headquartered in Shenzhen, the People?s Republic of China.

Advisors' Opinion:
  • [By Lisa Levin]

    VisionChina Media (NASDAQ: VISN) surged 5.71% to $30.00. The volume of VisionChina Media shares traded 237% higher than normal. VisionChina Media is expected to hold extraordinary general meeting of shareholders on April 24, 2014.

  • [By Monica Gerson]

    VisionChina Media (NASDAQ: VISN) soared 5.13% to $32.80 in the pre-market trading. VisionChina's trailing-twelve-month revenue is $98.39 million.

    The Dow Chemical Company (NYSE: DOW) surged 0.90% to $45.00 in the pre-market session. Dow Chemical's trailing-twelve-month revenue is $56.61 billion.

Top Life Sciences Stocks To Own Right Now: Trovagene Inc (TROV)

TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.

On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.

In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Advisors' Opinion:
  • [By Daniel Lauchheimer]

    In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.

  • [By Roberto Pedone]

    TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.

    Friday's Volume: 712,000

    Three-Month Average Volume: 183,106

    Volume % Change: 294%

    From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.

    Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.

Top Life Sciences Stocks To Own Right Now: Starz (STRZA)

Starz, formerly Liberty Media Corporation, incorporated on May 7, 2007, is an integrated global media and entertainment company with operating units that provide subscription video programming on domestic United States pay television channels (Starz Channels), global content distribution (Starz Distribution) and animated television and movie production (Starz Animation). As of January 14, 2013, the Company�� network included Starz, Encore, and Movieplex, Retroplex, Indieplex. Starz includes contemporary hit movies, original series and documentaries on six premium channels, available in high definition (HD) and hundreds On Demand. Encore includes favorite movies across eight themed movie channels, ENCORE HD, and an On Demand channel. Movieplex, Retroplex and Indieplex involves featuring a variety of movies packaged to match a mood or an attitude. As of January 14, 2013, the Company�� businesses included Anchor Bay Entertainment, Starz Worldwide Distribution, and Starz Digital Media. On January 11, 2013, Liberty Media Corporation (Liberty) and Starz announced the completion of the spin-off of Liberty from Starz. In connection with the spin-off, Starz changed its name from Liberty Media Corporation to Starz.

Starz Channels is a provider of premium subscription video programming through the flagship STARZ and ENCORE pay television (TV) networks, which showcase original programming and movies to United States multichannel video distributors, including cable operators, satellite television providers, and telecommunications companies. As of September 30, 2012, STARZ and ENCORE served a combined 55 million subscribers, including 21 million online offerings through STARZ PLAY, ENCORE PLAY, and MOVIEPLEX PLAY. Starz Distribution develops, produces and acquires entertainment content, distributing it to consumers globally on digital versatile disk (DVD), digital formats and traditional television. Starz Distribution's home video, digital media and worldwide distribution business units distribute! original programming content produced by Starz, as well as entertainment content for itself and third parties. Starz Animation produces animated TV and movie content for studios, networks, distributors and audiences worldwide.

Starz Digital Media is a distributor of digital and on-demand content. Starz Digital Media distributes original programming content (Starz and AMC), feature films (The Weinstein Company, Anchor Bay Films, RADiUS-TWC), anime (Manga Entertainment) and other filmed entertainment utilizing various business models, including download-to-own/electronic sell-through, video-on-demand, pay-per-view, subscription video-on-demand and ad-supported streaming. Starz Digital Media also programs and supports numerous ad-supported broadband channels and develops games, applications and other related content from many of its properties for distribution worldwide.

Anchor Bay Films is a division of Anchor Bay Entertainment and provides quality movie distribution with operations in the United States, United Kingdom, Canada, Australia, and offers distribution capabilities in other key territories. Anchor Bay Films offers the creative community an integrated distribution capability on all platforms and an international solution extending beyond the United States.

Starz Worldwide Distribution is a distributor of movies, televisions series, documentaries, children's programming, and other video content. Starz Worldwide Distribution licenses and syndicates Starz original series and other owned and licensed third party programming on a worldwide basis.

Advisors' Opinion:
  • [By Chris Katje]

    In January, Liberty Media (LMCA) completed the spin-off of Starz (STRZA). The newly separated company has key premium channel assets in the Starz and Encore brands. Starz also has developed a plan of creating original shows to coincide with its strong release of new movies. One new drama in development could turn out to be a sleeper hit for the network.

  • [By Lee Jackson]

    Starz (NASDAQ: STRZA) is a leading provider of premium subscription video programming through the flagship STARZ and ENCORE pay-TV networks. Recently spun off from Liberty Media Corp. (NASDAQ: LMCA), the company may soon be a takeover candidate for a larger entity hungry for content. The consensus target is set at $24.

Top Life Sciences Stocks To Own Right Now: Bombardier Inc (BDRAF)

Bombardier, Inc. is a Canada-based aerospace and transportation company. The Company operates in two segments: aerospace and rail transportation. The aerospace segment is structured by market segment (business aircraft, commercial aircraft and services), which is reflective of its organizational structure. The transportation segment is structured by market segment (rolling stock, services, system and signalling), which is reflective of its organizational structure, and by geographic region (Europe, North America, Asia-Pacific and Rest of world). As of December 31, 2012, the Company had 80 production and engineering sites in 26 countries, and a worldwide network of service centre. In May 2012, it launched the Learjet 70 and Learjet 75 aircraft programs. In October 2013, the Company announced that it has opened Bombardier's new wing manufacturing and assembly facility in Belfast. In December 2013, the Company sold Flexjet's activities to Flexjet, LLC. Advisors' Opinion:
  • [By Adam Levine-Weinberg]

    Yet there is a fourth major competitor in the commercial aircraft market -- Bombardier (NASDAQOTH: BDRAF  ) -- and it has its own advanced-technology airplane. The company's CSeries plane is expected to make its first flight as early as this week. Yet the CSeries put up a goose egg at the Paris Air Show, failing to notch a single order. While Bombardier has nearly 200 firm orders for the CSeries, the company will rapidly burn through that backlog once it starts CSeries mass production.

  • [By Quick Pen]

    Why are there talks about slowing down?
    In one of my previous articles where I was speaking of Bombardier�� (BDRAF) troubles because of the drop in oil prices, I had mentioned that analysts are expecting the oil prices to drop as low as $60 a barrel. It seems that time has come as Brent Crude oil price touched $60.79 a barrel according to NASDAQ. The following is chart shows the fluctuations in the Brent Crude Oil Spot Price. The latest spot price is as of December 15, 2014.

Tuesday, December 30, 2014

Top 10 Income Companies To Buy For 2014

Domino�� might not be the first place that comes to mind for the best slice in town but the retail chain is growing a lot faster than you might think.

Today the company said revenue was up 6.9% in the third quarter to $404 million while net income jumped 18% to $30.6 million.

But the real impressive story for Domino's Pizza Domino's Pizza is its long term strategy. You might recall back in 2009 its CEO famously acknowledged in a commercial that Domino�� pizza doesn�� taste good. He apologized for its poor ingredients and promised to improve the recipe.

His honesty worked; domestic same store sales grew 14.3% the following quarter. Since January 2010, shares of Domino�� have been crushing the competition rising 750% while Papa John�� grew 193%, Pizza Hut owner YUM! brands YUM! brands is up 93% and McDonalds 51%.

Top Insurance Companies To Own For 2015: CirTran Corp (CIRC)

CirTran Corporation, incorporated on March 23, 1987, manufactures, markets, and distributes internationally an energy drink under a license with Playboy Enterprises, Inc. (Playboy) through its subsidiary, CirTran Beverage Corporation. It operates in Beverage Distribution and Contract Manufacturing segments. In the United States, it provides a mix of high- and medium-volume turnkey manufacturing services and products using various high-tech applications for electronics original equipment manufacturers (OEMs) in the communications, networking, peripherals, gaming, law enforcement, consumer products, telecommunications, automotive, medical, and semiconductor industries. The Company�� services include pre-manufacturing, manufacturing, and post-manufacturing services.

Beverage Distribution

CirTran Beverage Corporation (CirTran Beverage) manufactures, markets, and distributes Playboy-licensed energy drinks, flavored water beverages, and related merchandise through various distribution channels. As of December 31, 2012, the Company had 65 countries throughout Europe, Africa, Australia, the Pacific, and the Middle East.

Contract Marketing

CirTran Products Corp. pursues contract-manufacturing relationships in the domestic consumer products markets, including products in areas, such as home/garden, kitchen, health/beauty, toys, licensed merchandise, and apparel for film, television, sports, and other entertainment properties. The Company concentrates its product development efforts into three areas: home and kitchen appliances, beauty products, and licensed merchandise. Through CirTran - Asia, Inc., the Company designs, manufactures, and supplies products in the international electronics, consumer products, and general merchandise industries for various marketers, distributors, and retailers selling overseas. This subsidiary provides manufacturing services to the direct-response and retail consumer markets.

The Company competes with Hansen�! � Energy, Diet Red, Monster Energy, Lost Energy, Joker Mad Energy, Ace Energy, Unbound Energy, Rumba energy juice, Red Bull, Rockstar, Full Throttle, No Fear, Amp, Adrenaline Rush, 180, Extreme Energy Shot, Red Devil, Rip It, NOS, Boo Koo, and Vitaminenergy.

Advisors' Opinion:
  • [By CRWE]

    Last Friday, CIRC remained (0.00%) +0.000 at $.0005 at the close (ref. google finance August 30, 2013 ��Close).

    CirTran Corporation has recently filed its Quarterly Report on Form 10-Q for the period ended June 30, 2013, showing continued growth in sales and a dramatic improvement in profits. CirTran�� sales were again driven by its Playboy Energy Drink line, which has grown to represent nearly 98% of revenues.

    For the quarter, CirTran previously reported sales of $1,096,691, a 247% increase over the $315,755 reported for the same period a year ago. For the six months ended June 30, 2013, CirTran reported sales of 1,964,843, a 110% improvement over the $934,455 reported for the first half of 2012.

Top 10 Income Companies To Buy For 2014: Ocado Group PLC (OCDO)

Ocado Group plc is a United Kingdom-based holding company. The Company�� principal activities are the retailing, logistics and distribution of grocery and consumer goods and the development and monetisation of intellectual property and technology for the online retailing, logistics and distribution of these goods. The Company is an online grocery retailer. The Company�� subsidiaries include Ocado Holdings Limited, Ocado Limited, Ocado Information Technology Limited, Last Mile Developments Limited and Last Mile Developments Limited. Advisors' Opinion:
  • [By Sarah Jones]

    Rio Tinto Group and Anglo American Plc (AAL) retreated more than 2.5 percent as copper and lead declined. Eurasian Natural Resources Corp. (ENRC) sank 6.8 percent as analysts downgraded the shares. Standard Life Plc slipped 1.2 percent as Chief Financial Officer Jackie Hunt resigned to move to a rival insurer. Ocado Group Plc (OCDO) fell for the first day this week as the online grocer ruled out a takeover by William Morrison Supermarkets Plc.

Top 10 Income Companies To Buy For 2014: Pacific Biosciences of California Inc.(PACB)

Pacific Biosciences of California, Inc., a development stage company, develops, manufactures, and markets an integrated platform for genetic analysis. The company engages in developing a technology platform that enables single molecule, real-time (SMRT) for the detection of biological processes. It primarily focuses on the deoxyribonucleic acid sequencing market. The company?s product includes the PacBio RS, a sequencing platform, which consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits. The company?s customers include genome centers, genomics service providers, and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Advisors' Opinion:
  • [By Geoff Gannon]

    1. Steel Excel (SXCL)
    2. FormFactor (FORM)
    3. Imation (IMN)
    4. Tuesday Morning (TUES)
    5. Pacific Biosciences (PACB)
    6. Maxygen (MAXY)
    7. Westell (WSTL)
    8. Volt Information Sciences (VISI)
    9. Yasheng Group (YHGG)

  • [By Alex Planes]

    However, Fool biotech expert Brian Orelli points out one big caveat: Once sequencing companies make these tests accessible, margins may collapse beyond the ability of volume sales to make up the difference. At least Illumina (and Life Tech) are in the driver's seat on margins, as it's unlikely that lesser-funded sequencing competitors Affymetrix (NASDAQ: AFFX  ) and Pacific Biosciences (NASDAQ: PACB  ) can muster the resources to push out sequencing at cost-effective scale before their peers.

Top 10 Income Companies To Buy For 2014: Carrizo Oil & Gas Inc.(CRZO)

Carrizo Oil & Gas, Inc., an independent energy company, engages in the exploration, development, and production of oil and gas in the United States and the United Kingdom. The company holds interest in crude oil and liquids plays in the Eagle Ford Shale in south Texas; the Niobrara Formation in Colorado; the Utica Shale in Ohio and Pennsylvania; and the Huntington Field in the U.K. North Sea. It also owns interest in natural gas plays in the Barnett Shale in North Texas; and the Marcellus Shale in Pennsylvania, New York, and West Virginia; as well as in the onshore Gulf Coast area and the Camp Hill field in Texas. As of December 31, 2011, the company had a proved oil and gas reserves of 935.6 billion cubic feet equivalent comprising 728 billion cubic feet of natural gas; 30.5 million barrels of oil or other liquid hydrocarbons (MMbbls) of oil and condensate; and 4.1 MMbbls of natural gas liquids, as well as operated 349 gross producing oil and gas wells. Carrizo Oil & Gas, Inc. was founded in 1993 and is based in Houston, Texas.

Advisors' Opinion:
  • [By Richard Moroney]

    Carrizo Oil & Gas (CRZO) focuses on proven shale properties in Colorado, Ohio, Pennsylvania, and Texas. Its Eagle Ford operations, which span more than 50,000 drillable acres in Texas, have estimated oil and gas reserves of 173 million barrels, or about 42% of Carrizo's total.

  • [By Aimee Duffy]

    Production results have fueled record numbers for producers big and small, including EOG Resources (NYSE: EOG  ) and Carrizo Oil & Gas (NASDAQ: CRZO  ) . EOG is the largest producer in the play, and production has exceeded management's expectations, reaching 153,000 barrels of oil equivalent per day by the end of the first quarter of this year. Carrizo is a much smaller operation, but its production has also exceeded management's expectations, reaching 9,500 bpd in the second quarter.

  • [By Robert Rapier]

    Eagle Ford crude driller Carrizo Oil & Gas (Nasdaq: CRZO) is up nearly 14 percent since we added it to the Aggressive Portfolio on Dec. 11, and here too there was no company-specific news. Rather, Carrizo appears to have benefited from the end in mid-December of the sharp autumn correction in drillers’ share prices.

Top 10 Income Companies To Buy For 2014: Flushing Financial Corporation (FFIC)

Flushing Financial Corporation operates as the holding company of Flushing Savings Bank, FSB that provides banking products and services primarily to consumers and businesses. The company?s deposit products include savings accounts, money market accounts, demand accounts, negotiable order of withdrawal accounts, and certificates of deposit. Its loan products portfolio comprises one-to-four family, multi-family residential, and commercial real estate mortgage loans; construction loans, primarily for residential properties; small business administration loans and other small business loans; mortgage loan surrogates, such as mortgage-backed securities; U.S. government securities, corporate fixed-income securities, and other marketable securities; and consumer loans, including overdraft lines of credit. The company also offers Internet banking services through iGObanking.com. As of December 31, 2010, it conducted its business through 16 full-service offices located in the New York City Boroughs of Queens, Brooklyn, and Manhattan, as well as in Nassau County, New York. The company was founded in 1929 and is based in Lake Success, New York.

Advisors' Opinion:
  • [By Tim Melvin]

    I always find it very interesting to see what long-term investors are selling in a given quarter. Kahn Brothers lightened up on many financials that have shot up and now trade above book value. The firm sold out of Flushing Financial (FFIC), TCF Financial (TCB) and Dime Community Bank (DCOM). Khan apparently shares my views on the large-cap drug stocks, easing up on both Pfizer (PFE) and Bristol Meyers (BMY) over the summer. Khan Brothers also sold the last of the Travelers shares (TRV) it has owned since 2008 at more than twice the purchase price.

Top 10 Income Companies To Buy For 2014: RAIT Financial Trust(RAS)

RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust (REIT). The company, through its subsidiaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate. It also offers a set of debt financing options to the commercial real estate industry along with fixed income trading and advisory services. In addition, RAIT Financial Trust owns and manages a portfolio of commercial real estate properties, and manages real estate-related assets for third parties. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. RAIT Investment Trust was founded in 1997 and is based in Philadelphia, Pennsylvania.

Advisors' Opinion:
  • [By Marc Bastow]

    Commercial real-estate loan originator and real estate investment trust RAIT Financial Trust (RAS) raised its quarterly dividend 6% to 17 cents per share, payable April 30 to shareholders of record as of April 4. At more than an 8% yield, RAS stock has the highest yield on this week’s list of dividend stocks.
    RAS Dividend Yield: 8.14%.

Top 10 Income Companies To Buy For 2014: Oncothyreon Inc .(ONTY)

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Advisors' Opinion:
  • [By James E. Brumley]

    On paper, Oncothyreon Inc. (NASDAQ:ONTY) doesn't look like a particularly compelling investment. The pre-revenue biotech company is poised to keep booking sizable losses as it continues to work on its lung cancer drug tecemotide (formerly Stimuvax), which has rejected by the FDA last year but is still being reworked for a slightly different illness than was being targeted initially. And, with no other Phase 3 drug in its pipeline, traders may be rightfully wondering if there's any real catalyst for ONTY in the foreseeable future.

  • [By Roberto Pedone]

    One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Oncothyreon (ONTY), which develops and markets synthetic vaccines and small molecules that treat cancer patients. This stock hasn't done much so far in 2013, with shares down modestly by 3.9%.

    If you take a look at the chart for Oncothyreon, you'll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last month and change, with shares moving between $1.63 on the downside and $1.95 on the upside. Shares of ONTY have been finding some buying interest of late right above its 50-day moving average of $1.73 a share. This stock is now starting to push within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.

    Traders should now look for long-biased trades in ONTY if it manages to break out above some near-term overhead resistance levels at $1.93 to $1.95 a share and then once it takes out more resistance at $1.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 689,364 shares. If that breakout triggers soon, then ONTY will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $2.12 a share to $2.70 a share.

    Traders can look to buy ONTY off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.73 a share or around more support at $1.63 a share. One can also buy ONTY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Monday, December 29, 2014

Top Medical Stocks To Own Right Now

Medical device maker Techne (NASDAQ: TECH  ) announced today that it's taking a 100% ownership stake in�Bionostics Holdings for $104 million cash.

Headquartered in�Devens, Mass.,�Bionostics makes proprietary quality control devices for diagnostic testing equipment and has�strategic supply relationships with virtually all global in vitro diagnostic-device OEMs.�Controls for blood glucose and blood gas devices are the largest portion of Bionostics' business, which generated�approximately�$29.3 million in revenues�for fiscal year 2012 that ended last Aug. 31.

Techne President and CEO�Charles R. Kummeth said: "The addition of Bionostics adds capabilities in exciting new areas like coagulation and expands our controls portfolio, giving us the critical mass we need to remain competitive and offer our customers continued value and options to serve their needs."

The acquisition is expected to be slightly accretive to Techne's fiscal year 2014 net earnings, even though there will be acquisition accounting charges related to the step-up in basis for acquired inventories and the amortization of intangibles. Since there are possible adjustments to the final price paid based on working capital available at the closing of the transaction, Techne said it couldn't�assess the final impact the deal will have on its first-quarter earnings per share or those for the entire fiscal year.

Top Medical Stocks To Own Right Now: Discount Dental Materials Inc (DDOO)

Discount Dental Materials, Inc. (DDM), incorporated on December 18, 2007, is a development-stage company. The Company focuses on selling disposable dental supply products at discount prices over the Internet. As of November 30, 2011, the Company had not generated any revenues.

The Company focuses on selling a limited number of products including burs (modern dental drills that can rotate at up to 800,000 revolutions per minute (rpm) and generally use hard metal rotary files). Dental burs come in a variety of shapes designed for specific applications. They are often made of steel with a tungsten carbide coating or of tungsten carbide entirely. The bur may also have a diamond coating), bearings, turbines and sterilization pouches. The Company uses a facility in Burbank, California to store and ship products.

The Company competes with Henry Schein and Patterson Dental.

Advisors' Opinion:
  • [By CRWE]

    Last Friday, DDOO previously surged (+5.00%) up +0.05 at $1.05 with 10,200 shares in play at the close (ref. google finance June 28, 2013 ��Close).

    Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

    Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

Top Medical Stocks To Own Right Now: Acceleron Pharma Inc (XLRN)

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.

The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.

The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.

Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

Top 10 Information Technology Companies To Watch In Right Now: Foundation Medicine Inc (FMI)

Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.

FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.

Advisors' Opinion:
  • [By John Udovich]

    If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

  • [By John Udovich]

    Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

  • [By Dan Caplinger]

    In the following video, Dan Caplinger, director of investment planning for The Motley Fool, looks at whether the IPO market is overheating once more. Dan points to some huge gains from recent IPOs, with FireEye (NASDAQ: FEYE  ) rising 80% in its first day while Rocket Fuel (NASDAQ: FUEL  ) and Foundation Medicine (NASDAQ: FMI  ) both posted gains of between 90% and 100%. Dan also highlights Sprouts Farmers Market� (NASDAQ: SFM  ) , which climbed a whopping 123% in its first day as a public company.

  • [By Lisa Levin]

    Foundation Medicine (NASDAQ: FMI) shares tumbled 7.58% to reach a new 52-week low of $21.23. Foundation Medicine's trailing-twelve-month profit margin is -147.08%.

Top Medical Stocks To Own Right Now: Koninklijke Philips NV (PHIA)

Koninklijke Philips NV, formerly Koninklijke Philips Electronics NV, is the Netherlands-based parent company of the Philips Group (Philips). The Company operates within three main business sectors, such as Healthcare, Consumer Lifestyle, and Lighting, as well as through the Innovation, Group & Services (IG&S) sector. The Healthcare sector offers both personal care and professional products, such as computer tomography equipment, radiography equipment and refurbished systems. Consumer Lifestyle sector offers a range of sound, vision, personal devices and household products, such as television, headphones, kitchen appliances, shavers and digital cameras, among others. Lighting sector offers lighting products, such as professional lamps, light-emitting diodes (LED), ballasts and luminaires, among others. The IG&S segment provides the operating sectors with support through shared service centers. It also includes projects which are not part of the operating sectors. Advisors' Opinion:
  • [By Corinne Gretler]

    European stocks rose for a fourth day, extending a seven-week high, as companies from UBS AG to Royal Philips (PHIA) Electronics NV reported increased profit.

Top Medical Stocks To Own Right Now: Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company�� ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs. The Company�� two advanced cancer programs are targeting mutations in the enzymes isocitrate dehydrogenase 1 and 2, referred to as IDH1 and IDH2. The Company�� drug candidates are selective for the mutated forms of IDH1 and IDH2 found in cancer cells versus the normal forms of IDH1 and IDH2 found in all other cells.

The Company focused on developing medicines to address IEMs, with a novel approach to these orphan diseases for which no effective or disease-modifying therapy is available. The Company has also de-validated and terminated numerous programs, including many that have been reported in scientific journals. In the Company�� IEM portfolio, it uses an equally rigorous set of validation techniques.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Equities Trading UP
    Sangamo Biosciences (NASDAQ: SGMO) shot up 16.32 percent to $22.81 announced the publication in the NEJM of the first-in-man study of genome editing using its ZFN technology. Shares of Agios Pharmaceuticals (NASDAQ: AGIO) got a boost, shooting up 27.72 percent to $40.41 after the company reported quarterly results. BJ's (NASDAQ: BJRI) was also up, gaining 21.04 percent to $33.48 after the company was upgraded toa Buy rating at Buckingham research.

  • [By Jake L'Ecuyer]

    Shares of Agios Pharmaceuticals (NASDAQ: AGIO) got a boost, shooting up 29.08 percent to $40.84 after the company reported quarterly results.

    Stage Stores (NYSE: SSI) was also up, gaining 13.47 percent to $22.41 after the company reported Q4 results and announced the sale of its Steele's off-price division to a new retail unit of Hilco Global.

  • [By Roberto Pedone]

     

    Another stock that insiders are moving into here is Agios Pharmaceuticals (AGIO), which focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism in the U.S. Insiders are buying this stock into major strength, since shares are up big so far in 2014 by 79%.

     

     

    Agios Pharmaceuticals has a market cap of $1.4 billion and an enterprise value of $1.5 billion. This stock trades at a premium valuation, with a price-to-sales of 53.91 and a price-to-book of 11.51. Its estimated growth rate for this year is 48.1%, and for next year it's pegged at 15%. This is a cash-rich company, since the total cash position on its balance sheet is $162.27 million and its total debt is zero.

     

    A director just bought 2,300 shares, or about $100,000 worth of stock, at $43.98 per share.

     

    From a technical perspective, AGIO is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been selling off after a failed breakout attempt for the last few weeks, with shares moving lower from its high of $50.37 to its intraday low of $42.15 a share. That move is quickly pushing shares of AGIO within range of tagging its 50-day moving average of $40.27 a share.

     

    If you're bullish on AGIO, then I would look for long-biased trades as long as this stock is trending above its 50-day at $40.27 and then once it breaks out above some near-term overhead resistance at $45 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 419,691 shares. If that breakout starts soon, then AGIO will set up to re-test or possibly take out its next major overhead resistance level at its all-time high of $50.37 a share. Any high-volume move above that level will then give AGIO a chance to tag $55 to $60 a share.

  • [By Lisa Levin]

    Agios Pharmaceuticals (NASDAQ: AGIO) shares touched a new 52-week low of $18.83. Agios Pharmaceuticals' trailing-twelve-month profit margin is -102.87%.

Top Medical Stocks To Own Right Now: MedeFile International Inc (MDFI)

Medefile International, Inc.(Medefile), incorporated on July 16, 1997, through its MedeFile, Inc. subsidiary, has developed a patient-centric, Internet-enabled Personal Health Record (iPHR) system for gathering, digitizing, maintaining, accessing and sharing an individual's actual medical records. MedeFile's products and services are designed to provide healthcare providers with the ability to reference their patient's actual past medical records.

MedeFile iPHR

MedeFile is a Business-to-Business and a Business-to-Consumer subscription service. MedeFile is designed to create a cradle to grave longitudinal record for each of its members by retrieving and consolidating copies of their medical records. When the records are received, the MedeFile system consolidates them into a single medically correct format. The records are then stored in Medefile's MedeVault, a secure repository that can be accessed by MedeFile members 24 hours a day, 7 days a week.

MedeFile's Emergency Medical Information (EMI) Card

Upon becoming a MedeFile member, each individual will receive a Membership / Emergency Medical Information (EMI) Card. It contains instructions on how to contact MedeFile in order to retrieve the member's medical records.

The Digital Health Profile (DHP)

A part of a member's MedeFile is their Digital Health Profile (DHP). This form is completed by the patient in order to provide a summary of the patient's healthcare history which assists healthcare providers in understanding the patient's course of medical treatment.

MedeDrive

The MedeDrive is an external universal serial bus (USB) drive, which stores all of a patient's Emergency Medical Information and their MedeFile which can be viewed on a personal computer. MedeDrive self loads its own viewer, so no special program or software is required.

MedeVault

The MedeVault is designed to serve as an electronic data and document repo! sitory that incorporates state-of-the-art security features in order to prevent unauthorized access to a patient's records. Access to the MedeVault is provided through an encrypted connection to a Web service run by MedeFile. This connection is provided by Secure Sockets Layer (SSL) technology.

MedeMinder

MedeMinder is MedeFile's reminder service. The member tells the Company when and where to call, and the Company automatically contacts the member day or night with an appropriate reminder, spoken by real people.

MedePro

During the year ended December 31, 2011, the Company introduced MedePro. MedePro is a medical record retrieval and document management solution created specifically by MedeFile for legal and insurance professionals.

SecurMed

SecurMed is designed to serve as an authentication process. SecurMed protects against any information being viewed by unauthorized persons.

The Company competes with GE Healthcare, Bio-Imaging Technologies, and Cyber Records.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap healthcare and lifestyle stocks Axxess Pharma Inc (OTCMKTS: AXXE), Medefile International Inc (OTCMKTS: MDFI) and Intelligent Living Inc (OTCMKTS: ILIV) have all been getting some extra attention lately thanks in part to a few disclosed paid promotions or investor relations type of activities. But just how healthy are these small cap stocks for investors and traders alike? Here is a quick reality check:

Top Medical Stocks To Own Right Now: Opt-Sciences Corp (OPST)

Opt-Sciences Corporation, incorporated on November 1956, conducts its business through its wholly owned subsidiary, O and S Research, Inc. The Company deposits anti-glare and/or transparent conductive optical coatings on glass used primarily to cover instrument panels in aircraft cockpits. It also provides full glass cutting, grinding and painting operations, which augment its optical coating capabilities. Its products are designed to enable pilots to read aircraft instruments in direct sunlight or at night or in covert situations using appropriate night vision filters or to protect the instruments from electromagnetic interference. The Company�� business is dependent on a robust commercial, business, and regional aircraft market and to a lesser degree the military aircraft market. It generally has a four to twelve week delivery cycle depending on product complexity, available plant capacity and required lead time for specialty raw materials, such as polarizers or filter glass.

The Company�� offers incorporate an optical coating of some type. Its primary coatings are for aircraft cockpit display applications and consist of its anti-reflection coating used for glare reduction and its transparent conductive coating used for electromagnetic interference shielding. In addition, it also offers a full range of other specialty instrument glass, including night vision filter glass, circular polarizers, touchpads, glass sandwiches for liquid crystal displays (LCDs) as well as other custom designed specialty glass components and assemblies. It uses its technology to apply a micro thin optical non-glare and/or conductive coating to the glass. Both processes utilize the deposit of a thin film of metal or metal oxide on the surface of the glass. The process takes place in a heated vacuum chamber. It heats the deposited material to over 1800 degrees Centigrade causing it to evaporate.

The Company competes with JDSU, Mod A Can, Dontech, Schott Glass and Hoya Optics

Advisors' Opinion:
  • [By Geoff Gannon] ng>Micropac

    Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.

    ADDvantage

    ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.

    By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.

    That�� pretty typical in the world of net-nets.

    Solitron

    Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.

    In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.

    OPT-Sciences

    This company is controlled by Arthu

Top Medical Stocks To Own Right Now: PTC Therapeutics Inc (PTCT)

PTC Therapeutics, Inc., incorporated on March 31, 1998 , is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes. The Company�� lead product candidate includes ataluren, which is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Ataluren is in late stage clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations (nmDMD) and cystic fibrosis caused by nonsense mutations (nmCF).

Ataluren is orally administered small-molecule compound that targets nonsense mutations. The Company is engaged in the development of ataluren for the treatment of genetic disorders in, which a nonsense mutation is the cause of the disease. Genetic tests are available for many genetic disorders, including Duchenne muscular dystrophy and cystic fibrosis, to determine if the underlying cause is a nonsense mutation. The EMA has designated ataluren as an orphan medicinal product for the treatment of nmDMD and nmCF. During the year ended December 31, 2012, the Phase III clinical trial completed. The Company�� Ataluren clinical trials in patients with nonsense mutation genetic disorders include Ataluren for nmDMD: Phase 2b clinical trial complete; Confirmatory Phase III clinical trial initiated, and Ataluren for nmCF: Phase III trial completed.

Advisors' Opinion:
  • [By WWW.DAILYFINANCE.COM]

    Records fell on Wall Street Friday as another solid report on housing lifted the market for the second day in a row. There's a three-day weekend coming up -- something that often prompts investor caution -- but the gains were broad-based even though volume was fairly light. The VIX, which measures volatility, fell to its lowest level this year. The Dow Jones industrial average (^DJI) gained 63 points, the Nasdaq composite (^IXIC) rose 31, and the Standard & Poor's 500 index (^GPSC) added 8, topping the record high set last week. The Dow Transportation average also raced to an all-time high, lifted by airline stocks. United (UAL) soared more than 4 percent; Delta (DAL) gained more than 1 percent and Southwest (LUV) gained 2 percent. Southwest is at an all-time high, up 79 percent from a year ago. New home sales bounced back with a better than expected 6.4 percent increase last month. Lennar (LEN) and D.R. Horton (DHI) both rose 4 percent. Pulte (PHM), Beazer (BZH) and Hovnanian (HOV) also solid posted gains. Earnings continue to drive retail stocks. Gap (GPS) edged higher even though net fell. Foot Locker (FL) gained 1½ percent after topping expectations. GameStop (GME) rose 4 percent. Its net rose, helped by the rollout last year of new Xbox and PlayStation consoles. Zumiez (ZUMZ) rose 5½ percent on an earnings beat. But Aeropostale (ARO) tumbled 24 percent. Its loss widened and sales declined. The retailer continues to struggle with teen fashion trends. Also on the earnings front, TiVo (TIVO) rose 2 percent as it swung to a profit from a year ago loss. It also reported an increase in the number of subscribers. Hewlett-Packard (HPQ) rose 6 percent on news the company plans to eliminate up to 16,000 additional workers in an effort to cut costs. And several stocks extended big moves from yesterday. Best Buy (BBY) rose more than 3 percent for the second straight day after earnings beat expectations. Isis Pharmaceuticals (ISIS) jumped
  • [By John Kell]

    PTC Therapeutics Inc.(PTCT) said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the biopharmaceutical company’s marketing authorization application for its muscular dystrophy treatment. Shares slumped 21% to $20.60 in premarket trading.

Top Medical Stocks To Own Right Now: Ophthotech Corp (OPHT)

Ophthotech Corporation, incorporated on January 05, 2007, is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company�� advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.

The anti-VEGF market for the treatment of wet AMD consists predominantly of two drugs that are approved for marketing and primarily prescribed for the treatment of wet AMD, Lucentis and Eylea, and off-label use of the cancer therapy Avastin. The use of anti-VEGF drugs has significantly improved visual outcomes for patients with wet AMD who have been treated with these drugs as compared to untreated patients.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Shares of Ophthotech (NASDAQ: OPHT) got a boost, shooting up 25.78 percent to $39.54 after the company reported that it has entered into an ex-US licensing and commercialization deal with Novartis Pharmaceuticals.

  • [By John Udovich]

    The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

  • [By Todd Campbell]

    That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.

Top Medical Stocks To Own Right Now: Five Prime Therapeutics Inc (FPRX)

Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

FP-1039

FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.

FPA008

FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.

FPA144

FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.

Advisors' Opinion:
  • [By Monica Gerson]

    Breaking news

    Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.

    Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

  • [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]

    Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)

Saturday, December 27, 2014

Top 10 Safest Companies To Own For 2014

I'll admit it. The traditional grocery business isn't an exciting industry for investment potential. Profit margins are low, with almost zero chance of spiking higher. Meaningful sales growth is hard to find, too. And grocery stores suffer from the constant threat of having more nimble retailers push into their markets, as we saw with Amazon.com's latest expansion of its food delivery business.

However, the safest path to big investment returns is through buying into years of predictable growth at a reasonable price. That's why I think Kroger (NYSE: KR  ) stock could be a great option for long-term investors right now.

Kroger chugs along
The grocer's latest earnings show the kind of steady results that most companies can only dream about. With a 3.3% boost in sales, Kroger notched its 38th consecutive quarter of growth at its existing stores. Customers responded to the company's investments in its locations by making more frequent visits, and by purchasing more products per trip. Packed register lines brought quarterly revenue to an all-time high $30 billion, and profits were up about 10%, to $481 million.

10 Best Wireless Telecom Stocks For 2015: TASER International Inc.(TASR)

TASER International, Inc. develops, manufactures, and sells electronic control devices (ECD) for use in the law enforcement, military, corrections, private security, and personal defense markets. ECDs transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system. Its products for the law enforcement, military, corrections, and professional security market include the TASER X26 product line, which consists of TASER X26, various cartridges, a digital power magazine, data download software and equipment, extended warranties, and a range of holstering options and accessories; TASER X3, a multi-shot ECD that would engage three separate targets; and ADVANCED TASER M26 product line comprising the ADVANCED TASER M26, various cartridges, rechargeable batteries, a battery charging system, data download software and equipment, extended warranties, and various holstering options and accessories. The company also provides TASER XREP, a self-contained, wireless ECD that deploys from a 12-gauge pump-action shotgun; and TASER Shockwave security system for safety and stand-off capability during hostile situations. In addition, it manufactures TASER C2, TASER X26C, and ADVANCED TASER M26C devices for the personal defense market, as well as provides various cartridges and other accessories. The company sells its products worldwide through its direct sales force, distribution partners, online store, and third-party resellers. TASER International, Inc. was founded in 1993 and is headquartered in Scottsdale, Arizona.

Advisors' Opinion:
  • [By Rich Smith]

    TASER International (NASDAQ: TASR  ) has landed another large order of its eponymous stun guns. On Tuesday, the Scottsdale, Ariz.-based weapons maker announced that the San Diego Sheriff's Department has ordered 1,200 upgraded X2 "Smart Weapons."

  • [By Lee Jackson]

    TASER International Inc. (NASDAQ: TASR) is on a growth path, having reported double-digit revenue increases for eight quarters in a row. The company claims to produce “the world’s safest and most effective weapons” that are becoming popular with the U.S. police departments. TASER’s stun guns practically have no serious competition. J.P. Morgan has a $20 target, and the consensus target is $20.33. TASER closed Tuesday at $18.50.

  • [By James E. Brumley]

    On the surface, the press release in and of itself may seem benign ... almost innocuous. When you start to proverbially put two and two together, however, this morning's news from View Systems Inc. (OTCBB:VSYM) could actually be early notice that things are about to change for the young, small company. By digging deeper into the details, it becomes clear that VSYM could become in Brazil what TASER International, Inc. (NASDAQ:TASR) and OSI Systems, Inc. (NASDAQ:OSIS) have become in the United States - security icons. View Systems shareholders could be on the same bullish receiving end of things that OSIS and TASR shareholders were on when each of those companies were experiencing a growth spurt a few years back.

  • [By Ben Levisohn]

    Taser International (TASR) has been on a tear–and JPMorgan says it’s now time to take profits on the maker of stun guns and other products.

    Getty Images

    As I noted yesterday, Taser’s been on quite a roll–the stock has gained more than 30% during the past month of trading. At that’s reason enough for JPMorgan’s Paul Coster, Mark Strouse and Paul Chung to cut its shares to Neutral from Overweight. They write:

    We are downgrading TASR to Neutral based on valuation. The stock has increased 36% in the past two weeks (SP500 down 3.7%), is up over 30% YTD, and is trading very close to our December 2014 price target of $12.00. While we remain constructive regarding TASR�� fundamentals owing to the ECD upgrade cycle and adoption of the Evidence.com video solution, we believe risk/reward is now balanced and we look for pullbacks to potentially add to positions.

    Taser has dropped 4% this morning after gaining 33% during the past month. That gain would have put it in the top-ten in the S&P 1500 if it were a member of� the index, behind Questcor Pharmaceuticals (QCOR), which has gained 36%, healthcare company Amedisys (AMED) and Affymetrix (AFFX), which has gained 44%, among others.

Top 10 Safest Companies To Own For 2014: Vanguard Energy Index ETF (VDE)

Vanguard Energy ETF, formerly known as Vanguard Energy VIPERs, is an exchange-traded share class of Vanguard Energy Index Fund (the Fund). The Fund employs a passive management or indexing investment approach designed to track the performance of the Morgan Stanley Capital International (MSCI) US Investable Market Energy Index (the Index), an index of stocks of large, medium and small United States companies in the energy sector, as classified under the Global Industry Classification Standard (GICS).

This GICS sector is made up of companies whose businesses are dominated by activities, such as the construction or provision of oil rigs, drilling equipment, and other energy-related service and equipment (such as seismic data collection), or companies engaged in the exploration, production, marketing, refining and/or transportation of oil and gas products. The Fund seeks to replicate the Index by investing all, or substantially all, of its assets in the stocks that make up the Index.

Advisors' Opinion:
  • [By MONEYMORNING.COM]

    I like the idea of investing in a group of the largest integrated energy companies, oil and gas explorers/producers, and energy equipment and services. It's like a call option on energy with no expiry date. One of the best alternatives in this sector is the Vanguard Energy ETF (NYSE: VDE).

Top 10 Safest Companies To Own For 2014: Compass Diversified Holdings (CODI)

Compass Diversified Holdings is a public investment firm specializing in acquiring controlling stakes in small to middle market companies. The firm seeks to make middle market and buyout investments. It seeks to invest in industries such as manufacturing, distribution, consumer products, and business services. The firm prefers to invest in companies based in North America with a preferred transaction size between $60 million and $300 million in value, cash flows between $5 million and $40 million, with enterprise values between $50 million and $250 million, and a minimum EBITDA of $10 million. It seeks to acquire controlling ownership interests in its portfolio companies and can also make additional platform acquisitions. The firm makes investments through balance sheet. Compass Diversified Holdings was founded in 2005 and is based in Westport, Connecticut. Compass Diversified Holdings operates as a subsidiary of The Compass Group LLC.

Advisors' Opinion:
  • [By Eric Volkman]

    Compass Diversified Holdings (NYSE: CODI  ) is holding its dividend steady for its Q2. For the tenth quarter in a row, the company will pay a distribution of $0.36 per share, the company announced this week.

  • [By Rick Munarriz]

    Compass Diversified Holdings (NYSE: CODI  ) owns several middle-market businesses. From printed circuit boards to gun safes -- from upholstered furniture to personal hydration products -- Compass lives up to the "Diversified" in its moniker.

  • [By Rick Munarriz]

    I went out on a limb last week, and now it's time to see how that decision played out.

    I predicted that Clean Energy Fuels (NASDAQ: CLNE  ) would close higher on the week. The provider of natural gas fueling solutions for transportation has been posting narrowing losses, and Wall Street was eyeing a 35% surge in revenue. The company was a solid report. Revenue came in a little light, but bottom-line results improved nicely. Shares of Clean Energy Fuels moved slightly higher on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market had a strong run this week, fueled be encouraging economic news. Secondary stocks led the way, with the Nasdaq soaring 1.7% on the week. The Dow managed to close just 1% higher. I was right. My final call was for Compass Diversified Holdings (NYSE: CODI  ) to beat Wall Street's quarterly profit target. The investor in several middle-market companies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a profit of $0.36 a share during the quarter, but Compass Diversified failed to beat the prognosticators. I was wrong.

    Two out of three? I'll take it. That makes me eight of nine over the past three weeks.

Top 10 Safest Companies To Own For 2014: CLARCOR Inc. (CLC)

CLARCOR Inc. provides filtration products, filtration systems and services, and consumer and industrial packaging products worldwide. Its Engine/Mobile Filtration segment offers oil, air, fuel, coolant, transmission, and hydraulic fluid filters for engines used in stationary power generation and mobile equipment applications, as well as for marine, construction, industrial, mining, and agricultural equipment. This segment also provides dust collection cartridges for environmental filtration applications The company�s Industrial/Environmental Filtration segment manufactures specialty industrial process liquid filters; filters for pharmaceutical processes and beverages; filtration systems, filters, and coalescers for the oil and natural gas industry; filtration systems for aircraft refueling, anti-pollution, sewage treatment, and water recycling; bilge water separators; sand control filters for oil and gas drilling; and woven wire and metallic products for filtration of pl astics and polymer fibers. This segment also offers antimicrobial treated filters and electronic air cleaners for use in commercial and residential buildings, hospitals, factories, residences, paint spray booths, gas turbine and dust collector systems, medical facilities, motor vehicle and aircraft cabins, clean rooms, and compressors. Its Packaging segment provides metal, plastic, and a combination of metal/plastic containers and closures for packing dry and paste form products, smokeless tobacco products, lip balms, ointments, and consumer healthcare products. This segment also offers shells for dry batteries; canisters for films and candles; spools for insulated and fine wire; and custom decorated flat metal sheets. The company distributes its products through independent distributors, dealers for original equipment manufacturers, retail stores, and internal sales force, as well as directly to end-use customers. CLARCOR Inc. was founded in 1904 and is headquartered in Fra nklin, Tennessee.

Advisors' Opinion:
  • [By Diane Alter]

    Dividend Stocks That Increased Payout in September

    Accenture plc (NYSE: ACN) announced a 14.8%, or $0.12 per share, increase to its semiannual dividend. The management consulting firm will now pay a semiannual dividend of $0.93. Shares yield 2.53%. Agruim Inc. (NYSE: AGU) boosted its dividend by $1.00 per share to a total dividend of $3.00 on an annualized basis. Shares of the global retailer of agricultural products now sprout a 3.54% yield. Air Industries Group Inc. (NYSE: AIRI) doubled its dividend to $0.125 per share. The maker of airplane and helicopter parts now floats a lofty yield of 6.6%. Alexandria Real Estate Equities Inc. (NYSE: ARE) upped its dividend 4.6% to $0.68 per quarter for a yield of 4.21%. Banner Corp. (Nasdaq: BANR) boosted its quarterly dividend 25% to $0.15 per share. The parent company of Banner and Islander Bank serves the Pacific Northwest region. Brady Corp. (NYSE: BRC) lifted its quarterly dividend 2.6% to $0.78 per share. It was the 28th straight dividend increase from the identification solutions company. Shares yield 2.57%. Campbell Soup Co. (NSE: CPB) raised its quarterly dividend to $0.31 per share, up from $0.29. The company last raised its dividend in November 2010. Shares yield a hearty 3.06%. CLARCOR Inc. (NYSE: CLC) raised its quarterly dividend 26% to $0.17 per share. It's the largest percentage increase from the Tennessee-based diversified marketer of mobile filtration and packaging products in the last 20 years, and it continues the company's consecutive streak of increasing dividends for the last 30 years. Franklin Resources Inc. (NYSE: BEN) boosted its quarterly dividend 2.6% to $0.10 per share. Frisch's Restaurants Inc. (NYSE: FRS) increased its quarterly dividend 12.5% to $0.18. Shares yield 3.10% The Goodyear Tire & Rubber Company (NYSE: GT), in a move that suggests good times are ahead, reinstated its dividend at $0.05 per share. Good

Top 10 Safest Companies To Own For 2014: Mechel Steel Group OAO (MTL)

Mechel OAO, together with its subsidiaries, engages in mining and steel businesses in the Russian Federation, other CIS countries, Europe, Asia, the Middle East, the United States, and internationally. The company operates through four segments: Mining, Steel, Ferroalloys, and Power. The Mining segment engages in the production and sale of metallurgical and steam coal, coke, iron ore, and limestone, as well as chemical products, such as coal tar, naphthalene, and other compounds. The Steel segment produces and sells semi-finished steel products, carbon and special long products, and carbon and stainless flat products, as well as metal products, including wire products, forgings, and stampings. The Ferroalloys segment is involved in the production and sale of nickel ore, low-ferrous ferronickel, ferrochrome, and ferrosilicon. The Power segment engages in the generation and sale of electricity and heat energy from steam coal; and power distribution activities. The company, f ormerly known as Mechel Steel Group OAO, was founded in 2003 and is based in Moscow, the Russian Federation.

Advisors' Opinion:
  • [By Fede Zaldua]

    According Citigroup's analysts its about time to start accumulating Mechel's (MTL) shares. The reason for the sharp upgrade (from sell to buy) was Mechel's recent deal with some of its creditors to ease part of the company's huge debt burden. More specifically, the Russian metals and mining company managed to seal a deal with the state controlled VTB Group through which it managed to get covenant holidays and a debt restructuring. That said, I don�� think Mechel is out from the woods and I do not think its time to buy the company's shares, even when the are down by 67% year-to-date (ytd).

  • [By Dan Caplinger]

    Finally, beyond the Dow, Russian steel company Mechel (NYSE: MTL  ) has spiked 10% after announcing a share buyback program. With steel producers having been down and out for a long time, investors should expect to see similar moves from other companies in the future. Weak financial conditions make it hard for companies to spare the cash for buybacks, but when shares are down and out, buybacks produce the best return for the company.

  • [By Jake L'Ecuyer]

    Mechel OAO (NYSE: MTL) was down, falling 2.33 percent to $2.52 after the company appointed Senior Vice-President for Economics and Management Oleg Korzhov as its Chief Executive Officer.

  • [By MONEYMORNING.COM]

    As a result, Russian stocks have generally been getting hammered. To keep the data clean and discrete, I ran the charts over the last three months. In that period, energy giants Gazprom OAO (OTC: OGZPY) and CNOOC Ltd. (ADR) (NYSE: CEO) are both off more than 18%. The steel company Mechel OAO (ADR) (NYSE: MTL) is off 24%.

Top 10 Safest Companies To Own For 2014: Limoneira Co(LMNR)

Limoneira Company engages in agribusiness and real estate development businesses primarily in the United States. The Company operates in three reportable operating segments; Agribusiness, Rental Operations, and Real Estate Development. The agribusiness segment farms, packages, and sells lemons directly to food service, wholesale, and retail customers. It also grows oranges, and a range of specialty citrus and other crops, such as pummelos, Moro blood oranges, Cara Cara oranges, Satsuma mandarin oranges, Minneola tangelos, pistachios, cherries, and Star Ruby grapefruits. This segment has approximately 1,766 acres of lemons; 1,254 acres of avocados; 1,062 acres of oranges; and 401 acres of specialty citrus and other crops Ventura and Tulare Counties, California. The Rental Operations segment rents residential and commercial facilities; leases land; and provides organic recycling services. This segment owns and maintains approximately 188 residential housing units located in Ventura and Tulare Counties; owns various commercial office buildings and a multi-use facility consisting of a retail convenience store, gas station, car wash, and quick-serve restaurant; and leases approximately 586 acres of land to third party agricultural tenants. The Real Estate Development segment develops land parcels, multi-family housing, and single-family homes. This segment has 1,873 units in various stages of planning and development. The company also processes and packs lemons lemons grown by third parties. Limoneira Company was founded in 1893 and is headquartered in Santa Paula, California.

Advisors' Opinion:
  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Limoneira (Nasdaq: LMNR  ) , whose recent revenue and earnings are plotted below.

  • [By John Udovich]

    Last Friday, small cap Farmland Partners Inc (NYSEMKT: FPI) had an IPO to join Gladstone Land Corp (NASDAQ: LAND), Alico, Inc (NASDAQ: ALCO) and Limoneira Company (NASDAQ: LMNR) as the latest option for retail investors seeking a way to invest in American farmland. After all, there is that old quote attributed to Mark Twain: "Buy land, they're not making it anymore." Moreover, February Wall Street Journal article noted that From 2009 to mid-2013, average prices for agricultural land in the�US rose by half while in Iowa, Nebraska and some other Midwest farm states, prices more than doubled. However, the same article noted that there is mounting evidence that the farmland�boom is fizzling out as�farmland prices in Iowa fell 3% over the second half of last year and those in Nebraska fell 1%. The good news though is that today's agricultural sector looks markedly different than it did during the last farmland bust back in�the early 1980s while Greyson Colvin, the managing partner at investment manager Colvin & Co. (which owns about 7,000 acres of farmland), was quoted as saying: "We think this next 12 months is going to be the best window we've had in the past five years [to invest in farmland].��/p>

  • [By Eric Volkman]

    Limoneira (NASDAQ: LMNR  ) is maintaining its dividend. The company this week declared a distribution of $0.03750 per share, to be handed out July 16 to shareholders of record as of July 8.

Top 10 Safest Companies To Own For 2014: Osiris Therapeutics Inc.(OSIR)

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Advisors' Opinion:
  • [By Lauren Pollock]

    Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.

  • [By Maxx Chatsko]

    Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR  ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.

  • [By Alexander Maxwell]

    One of the companies attempting to develop a better treatment for chronic diabetic foot ulcers is Osiris Therapeutics� (NASDAQ: OSIR  ) . Earlier this month, Osiris shares more than doubled as the company announced positive data for its CDFU drug Grafix. The study results were very impressive to say the least; the study was stopped early due to the overwhelming efficacy exhibited by the treatment. A main highlight is the fact that 62% of Grafix patients had their wound closed at 12 weeks, compared to only 21% of patients using conventional methods. Clearly, the efficacy in this endpoint was overwhelming. Grafix also achieved all of the secondary endpoints for the trial, and more importantly demonstrated a relatively benign safety record.�